Abstract 100P
Background
Liquid biopsy for circulating tumor DNA is a valuable tool for cancer treatment selection and monitoring but other technologies must be explored to reveal actionable biomarker expression in the blood. We present a novel method to infer biomarker expression from cell-free non-coding small RNAs (smRNAs), including orphan non-coding RNAs (oncRNAs), which are actively secreted and stable in blood. Our platform uses smRNAs as surrogates for tumor transcriptomes and can infer biomarkers in breast cancer patients from 1 ml of plasma.
Methods
We developed a cell-free smRNA assay with an automated, CLIA-certified lab workflow. We screened the smRNA transcriptome to identify smRNAs associated with ESR1 and ERBB2 mRNA expression across breast cancer subtypes in tumor tissue (n=540). We developed a model in tumor and validated our expression scores with published RNA-seq in tumor tissue (TCGA), breast cancer cell lines with conditioned media (RNA-seq from DepMap) (n=10), and plasma from Stage III and IV breast cancer patients (n=75) with immunohistochemistry (IHC) derived hormone receptor (ER and HER2) status.
Results
From 3856 smRNA features, we developed separate smRNA scores for ESR1 and ERBB2 expression. In tumor tissue, we observed strong correlation between smRNA score and mRNA-seq for ESR1 (r=0.81, 95% CI: 0.78-0.84) and ERBB2 (r=0.79, 0.72-0.84), as well as with IHC status (ER, AUC = 0.96, 0.94-0.98; HER2, AUC = 0.87, 0.8-0.94). We confirmed that our scores were calibrated for conditioned media from common breast cancer cell lines with known ER and HER2 status, such that extracellular smRNA scores correlated with mRNA levels (r = 0.83 ERBB2, r = 0.79 ESR1). smRNA scores for baseline patient plasma predicted ER status in HER2- patients (AUC=0.79, 0.62-0.96) and HER2 status in HR- patients (AUC=0.85, 0.45-0.89).
Conclusions
We present the first use of cell-free small RNAs in an automated liquid biopsy assay to accurately infer breast cancer biomarkers from transcriptional profiles. This approach provides a sensitive option to assess potential drug target activity from a single blood draw.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Exai Bio.
Funding
Exai Bio.
Disclosure
L.S. Schwartzberg, E. Boyle, T. Cavazos, M. Karimzadeh, L. Fish, F. Hormozdiari: Financial Interests, Institutional, Full or part-time Employment: Exai Bio. J. Yen: Financial Interests, Institutional, Full or part-time Employment: Exai Bio; Financial Interests, Personal, Stocks/Shares, Former Employee: Guardant Health. H. Heydari: Financial Interests, Institutional, Financially compensated role: Exai Bio. R. Trivedi: Financial Interests, Institutional, Full or part-time Employment: Exai Bio; Financial Interests, Personal, Stocks/Shares, Former Employee: Illumina. A. Lazar: Financial Interests, Institutional, Advisory Role: Exai Bio. B. Alipanahi: Financial Interests, Institutional, Full or part-time Employment: Exai Bio; Financial Interests, Personal, Stocks/Shares: AstraZeneca, Ionis Pharmaceuticals, Moderna Therapeutics, Guardant Health, 23andMe.
Resources from the same session
1812TiP - IDeate-Lung03: A Phase Ib/II study of ifinatamab deruxtecan (I-DXd) plus atezolizumab (atezo) with or without carboplatin (carbo) as first-line (1L) induction or maintenance in patients (pts) with extensive stage (ES) small cell lung cancer (SCLC)
Presenter: Charles Rudin
Session: Poster session 07
1813TiP - Debio 0123, a highly selective WEE1 inhibitor, combined with carboplatin (CP) and etoposide (ETOP) in patients (pts) with small cell lung cancer (SCLC) that progressed after platinum-based therapy: A phase I dose escalation and expansion study
Presenter: Valentina Gambardella
Session: Poster session 07
2P - Single-cell profiling and integrative TCR analysis reveals tumor-mutation associated phenotypes and immune repertoire in lung adenocarcinoma
Presenter: Alexander Lozano
Session: Poster session 07
3P - Metabolic reprogramming induced by KEAP1 mutation in NSCLC
Presenter: Renata Akhmetzianova
Session: Poster session 07
4P - CBL-B inhibition overcomes PD-1/LAG-3 mediated resistance in lung cancer
Presenter: Luisa Chocarro
Session: Poster session 07
5P - Circulating tumor cell-derived organoids from lung adenocarcinoma patients for assessment of EGFR and KRAS mutations
Presenter: Mohamed Lahmadi
Session: Poster session 07
6P - Circulating low-density neutrophils (LDNs) are associated with resistance to immunotherapy as frontline treatment for non-small cell lung cancer (NSCLC): Updated results and proteomic characterization
Presenter: Natalia Castro Unanua
Session: Poster session 07
7P - Association study between genetic variants in regulatory gene for RNA modification and prognosis in non-small cell lung cancer
Presenter: Eungbae Lee
Session: Poster session 07
8P - Profiling of zidesamtinib and other ROS1 inhibitors in an intracranial CD74-ROS1 G2032R preclinical model
Presenter: ANUPONG TANGPEERACHAIKUL
Session: Poster session 07
9P - Small-extracellular vesicles derived from NSCLC cells dampen the CD8+ T cell response against tumor
Presenter: Manon CHANG
Session: Poster session 07